Balyasny Asset Management
RANI icon

Balyasny Asset Management’s Rani Therapeutics RANI Stock Holding History

Balyasny Asset Management’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.68K Sell
2,206
-3,693
-63% -$3.27K ﹤0.01% 2949
2026
Q1 		$4.33K Sell
5,899
-8,756
-60% -$11.2K ﹤0.01% 2804
2025
Q4 		$19.8K Buy
+14,655
New +$22.1K ﹤0.01% 3017

Other funds holding RANI

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $433M AUM 8.59% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Balyasny Asset Management's RANI Position: Q2 2026 in Review

Balyasny Asset Management reduced its Rani Therapeutics (RANI) stake by 63% in Q2 2026, selling an estimated $3.27K and leaving 2,206 shares worth $1.68K. The position accounts for ﹤0.01% of the portfolio, ranked #2949.

Balyasny Asset Management first reported a position in RANI in Q4 2025 and has held it in 3 quarters since. The position peaked at $19.8K in Q4 2025. 68 funds tracked by Wall St. Rank hold RANI as of Q2 2026.

  • Balyasny Asset Management held 2,206 shares of Rani Therapeutics worth $1.68K as of Q2 2026.
  • Balyasny Asset Management sold 3,693 Rani Therapeutics shares in Q2 2026, an estimated $3.27K.
  • Rani Therapeutics made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #2949 holding.
  • Balyasny Asset Management first reported a position in Rani Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Balyasny Asset Management's Rani Therapeutics position peaked at $19.8K in Q4 2025.
  • 68 funds tracked by Wall St. Rank held Rani Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.